is the fda stopping compounded semaglutide Hims & Hers stock falls 25% as curtails GLP-1s FDA faces new lawsuit from

Future clinical trials should aim to distinguish the direct analgesic effects of GLP-1RAs from their metabolic benefits and explore their broader applications in pain conditions

The 2025 World Health Organization guideline now recommends GLP-1 therapies (liraglutide, semaglutide, and tirzepatide) as part of long-term obesity treatment in adults, paired with lifestyle interventions (WHO)

The truth is neither comes without trade-offs

You might experience: Injection site reactions Headaches Mild gastrointestinal discomfort In fact, about 1 in 6 individuals may notice local injection site reactions

Together, theyre a powerhouse duo

Sometimes, the effect of the procedure can last up to several months